Bristol-Myers Squibb: all 2,184 studies

Page 15 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy VolunteersCompletedNCT03038711Phase 1
• Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy ParticipantsWithdrawnNCT03035734Phase 1
• Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male ParticipantsCompletedNCT03004768Phase 1
• Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial FibrillationWithdrawnNCT03002740
• Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible PatientsCompletedNCT03001804
• A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male AdultsCompletedNCT02994381Phase 1
• Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab TherapyCompletedNCT02990611
• A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy ParticipantsWithdrawnNCT02985632Phase 1
• Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy ParticipantsCompletedNCT02982707Phase 1
• Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple MyelomaCompletedNCT02976493
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's DiseaseWithdrawnNCT02974322Phase 3
• A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02973191Phase 1/2
• Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsCompletedNCT02966548Phase 1
• A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy SubjectsCompletedNCT02959060Phase 1
• A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult SubjectsCompletedNCT02957474Phase 1
• A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy SubjectsCompletedNCT02957448Phase 1
• Study of BMS-986012 in Subjects With Small Cell Lung CanerCompletedNCT02949895Phase 1
• A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in SpainCompletedNCT02946333
• Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior TherapyCompletedNCT02940639
• Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabCompletedNCT02935790Phase 1
• A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy SubjectsCompletedNCT02934269Phase 1
• Study With Healthy Japanese and Non-Asian Participants With BMS-986231CompletedNCT02932969Phase 1
• Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral AgentsWithdrawnNCT02928263
• A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCompletedNCT02922543
• A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy SubjectsCompletedNCT02922452Phase 1
• A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCompletedNCT02921828
• A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid TreatmentCompletedNCT02921815
• A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCompletedNCT02921802
• Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In ItalyCompletedNCT02921126
• Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy ParticipantsCompletedNCT02912234Phase 1
• Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior ChemotherapyCompletedNCT02910999
• Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain CancerCompletedNCT02903069Phase 1
• An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical PracticeCompletedNCT02902900
• A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis TreatmentCompletedNCT02902679Phase 1
• An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the NetherlandsCompletedNCT02891551
• Phase 1 Study of Mesothelin-ADCCompletedNCT02884726Phase 1
• Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male SubjectsCompletedNCT02880670Phase 1
• Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative ColitisTerminatedNCT02864264Phase 1
• Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology PracticesCompletedNCT02856646
• Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to NivolumabCompletedNCT02856451
• Early Patient Access Treatment Use Protocol CA204-220No longer availableNCT02856438
• Yervoy Pregnancy Surveillance StudyWithdrawnNCT02854488
• A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine ClearanceCompletedNCT02849444
• Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeCompletedNCT02847728
• Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab EmiratesCompletedNCT02845089
• A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
• Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in ScandinaviaCompletedNCT02839629
• ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTECompletedNCT02836457
• The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female SubjectsCompletedNCT02832180Phase 1
• Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus TrospiumCompletedNCT02831231Phase 1
• Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy SubjectsCompletedNCT02820935Phase 1
• A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy VolunteersCompletedNCT02819271Phase 1
• Trial of BMS-986012 in Combination With Platinum and EtoposideCompletedNCT02815592Phase 1
• Long-Term Follow-up Study for Patients Previously Treated With JCAR015CompletedNCT02813252
• A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy SubjectsCompletedNCT02807909Phase 1
• Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMSCompletedNCT02797015Phase 1
• Interferon Toxicities in Melanoma TreatmentCompletedNCT02794636
• Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) PatientsCompletedNCT02792335
• Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue TherapyCompletedNCT02791386
• A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy SubjectsCompletedNCT02790125Phase 1
• Longterm Follow-up of Subjects Treated With bb2121CompletedNCT02786511
• Study in Patients With Unresectable And Metastatic Melanoma: The Optimize StudyCompletedNCT02780089
• Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.SCompletedNCT02769078
• Safety Study of BMS-986202 in Healthy Subjects and to Treat PsoriasisCompletedNCT02763969Phase 1
• An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or OpdivoWithdrawnNCT02763761Phase 2
• A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe SubstratesCompletedNCT02762123Phase 1
• Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice SettingsCompletedNCT02758769
• Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - VenezuelaCompletedNCT02756481
• Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral AnticoagulantsCompletedNCT02754154
• Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])CompletedNCT02741544
• Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune DiseasesCompletedNCT02739386
• Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy SubjectsCompletedNCT02739373Phase 1
• Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or NilotinibCompletedNCT02733445
• Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in KoreaCompletedNCT02727933
• Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabCompletedNCT02719613Phase 2
• Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant MelanomaCompletedNCT02717364
• Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in FranceCompletedNCT02714855
• Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy SubjectsCompletedNCT02705989Phase 1
• Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and CanadaCompletedNCT02705833
• Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02692339
• Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's DiseaseTerminatedNCT02685683Phase 2
• Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the USCompletedNCT02674594
• A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic CancerTerminatedNCT02670746
• Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)CompletedNCT02661568
• Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k AntagonistsCompletedNCT02661516
• Study of bb2121 in Multiple MyelomaCompletedNCT02658929Phase 1
• Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical PracticeTerminatedNCT02655159
• Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With PainCompletedNCT02651363
• A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT02641002Phase 1
• APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM StudyCompletedNCT02640222
• Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung CancerTerminatedNCT02635061Phase 1
• Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU CountriesCompletedNCT02632890
• Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedNCT02631044Phase 1
• To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of CareCompletedNCT02626689
• Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic CancerCompletedNCT02620800Phase 1
• A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02616640Phase 1
• Safety and Tolerability Study of BMS-986177 in Healthy SubjectsCompletedNCT02608970Phase 1
• Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mgCompletedNCT02600468
• Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mLCompletedNCT02600455
• Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South AfricaCompletedNCT02598466

← Bristol-Myers Squibb overview and focus areas